BIDEN STEALS FROM SENIORS!

New Post Public Reply Private Reply Replies (0) Message Board
Rusty
251
BIDEN STEALS FROM SENIORS!

f5c17d506b88c02e8f25124c08b533c3.png

The Biden administration quietly announced last week that it will leave in place one of the largest-ever Medicare premium hikes for the remainder of 2022 , despite federal health officials' decision to restrict coverage of the expensive and potentially ineffective Alzheimer's drug that drove the increase.

Progressive healthcare advocates responded with outrage to the administration's Friday announcement, warning that it will inflict entirely avoidable financial pain on vulnerable seniors and hand the GOP an effective talking point heading into the November midterms.

"This is a terrible decision," Linda Benesch, communications director of Social Security Works, told Common Dreams. "Seniors should never have been forced to pay inflated Medicare premiums for an ineffective, dangerous, and massively overpriced drug."

"Not only is lowering Medicare premiums the right thing to do, it's also a political necessity," said Benesch.
"Older voters are a key force in midterm elections. Keeping Medicare premiums needlessly high until after the election is a gift to Mitch McConnell and his fellow Republicans.

Every Congressional Democrat who wants to keep their seat in November should join us in calling on the Biden administration to reverse this decision and lower Medicare premiums now!"

Warren Gunnels, the staff director for Sen. Bernie Sanders, I-Vt., similarly argued that the Biden administration's refusal to reverse the premium hike is both political and policy malpractice.

"Imagine being able to put more money in the pockets of senior citizens who are struggling to put food on the table right now and doing nothing instead," Gunnels wrote on Twitter. "This is how you blow a slam dunk."

First announced by the Centers for Medicare and Medicaid Services (CMS) last November, the monthly Medicare Part B premium increase of 14.5% over the 2021 rate—from $148.50 to $170.10—was enacted to account for the potentially massive cost that Biogen's Alzheimer's drug Aduhelm was expected to impose on the federal health program in 2022.

But in January, under pressure from progressive lawmakers and organizations, Health and Human Services Secretary Xavier Becerra instructed CMS to reexamine the 2022 Medicare premium hike in light of Biogen's decision to cut Aduhelm's annual price from $56,000 to $28,200.

And last month, CMS finalized its decision to restrict coverage of Aduhelm to Medicare patients enrolled in clinical trials, further undercutting the justification for the 2022 premium spike.

Citing CMS' Aduhelm coverage decision, Sanders—the chair of the Senate Budget Committee—pushed the Biden administration earlier this year to swiftly reverse the Medicare premium increase and refund seniors who had already paid the inflated price.

Benesch echoed that demand on Tuesday, arguing that "once Medicare rightfully decided not to cover Aduhelm in most circumstances, beneficiaries should have gotten a refund."

"We are going to keep organizing seniors to demand that the Biden administration reverse course and send Medicare beneficiaries the refund they deserve, along with lowering premiums for the rest of the year," said Benesch.

In a five-page analysis released Friday, CMS insisted that carrying out a mid-year change to Medicare's 2022 premiums would be "prohibitively complex and highly risky, requiring significant resources and unproven technical solutions from the varied entities which manage premium collection and payment."

The agency estimated that Medicare Part B's monthly premiums in 2022 would have been $160.30 instead of $170.10 if Aduhelm were removed from the equation.

"Potential Aduhelm costs resulted in roughly half of the 2022 premium increase," CMS said.

Becerra pointed to CMS' conclusion as evidence that the Biden administration's hands are tied by its own November decision to hike premiums in preparation for Aduhelm cost burdens.

Lamenting the "legal and operational hurdles" flagged by CMS, Becerra promised the administration will work to ensure that seniors see premium relief next year—cold comfort to those hurt by higher costs in 2022.

"After receiving CMS' report reevaluating the 2022 Medicare Part B premiums, we have determined that we can put cost-savings directly back into the pockets of people enrolled in Medicare in 2023," said Becerra. "We had hoped to achieve this sooner, but CMS explains that the options to accomplish this would not be feasible."

https://www.salon.com/2022/06/01/largest-ever...s_partner/
Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Faces Class Action: Investors Seek Justice

Updated Category News Views 85

When you hear a heavyweight like D-Wave Quantum Inc. finding itself tangled in a securities fraud lawsuit, you know there’s something big brewing. D-Wave Quantum Inc. NASDAQ: QBTS is under the spotlight and the clock is ticking. If you've dipped your toes into their stock between February 26, 2026, and August 25, 2026, chances are, this might be your ticket to seek some...

Continue Reading
Noma Hits Fortune Cyber 60 with AI Security Success

Updated Category News Views 63

Celebrating an AI Security Standout Well, look at that, Noma's found itself on the Fortune Cyber 60 list for 2026-2027. This listing isn't just some vanity metric. We’re talking about getting the nod from heavyweights like Lightspeed Venture Partners and Amazon Web Services. It recognizes them among 60 pivotal, venture-backed cybersecurity players, and sure, it’s in...

Continue Reading
Fashion Sees Quality Trumping Price in Consumer Preferences

Updated Category News Views 75

Consumers Are Shifting Away from Price-First Mindset You could always count on shoppers looking for a bargain, right? Well, hold your horses, 'cause that train's rolling off the tracks. In today's fashion shuffle, good ol' quality and craftsmanship are giving low prices a run for their money. A study spearheaded by Boston Consulting Group (BCG) and Women's Wear Daily...

Continue Reading
Bugsy Siegel's Cold Case: Museum Exhibit Revisits Unsolved Murder

Updated Category News Views 30

Whoever thought sleuthing around organized crime’s dark corridors would land you inside Las Vegas' Mob Museum, tracing the cold case trail of none other than Bugsy Siegel? Yeah, the notorious mobster whose murder on June 20, 1947, has remained frozen in mystery like a stiff in cement shoes. Now, as we inch closer to the 80-year mark since Siegel was shot dead in Beverly...

Continue Reading
Smartpress: Adobe & Canva Shape Print Design World

Updated Category News Views 54

Adobe's Stranglehold on Professional Design Over at Smartpress, they've pulled the curtain back on just how heavily Adobe Creative Suite weighs in on the print design sector. The company's recent analysis shines a light on the staggering 66% dominance of Adobe's InDesign and Illustrator in file submissions. That's a hefty portion influencing both the quality and financial...

Continue Reading
Peptide Therapy Rules Change: Gameday Ups the Ante

Updated Category News Views 0

Gameday Men's Health: Leading the Safe Peptide Charge Finally, we got some regulatory sanity stepping up to the plate with peptides. You see, the FDA's new interim policy is letting state-licensed compounding pharmacies work their magic with peptides, but only under strict medical watch. And Gameday Men's Health sure ain't wasting any time setting up shop in this fresh...

Continue Reading
A.O. Smith Sells 81% of China Arm to CPE: Key Takeaways

Updated Category News Views 116

When a major player like A.O. Smith decides to offload a piece of its business, folks tend to sit up and pay attention. This isn't just some run-of-the-mill shuffling. A.O. Smith has inked a deal with CPE to hand over an 81% stake in its China business. What does this transaction bring to the table and who stands to gain? Broken Down for the Curious Investor The numbers...

Continue Reading
transcosmos: Not Just Calls—Evolving Business Strategy

Updated Category News Views 67

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Continue Reading
Travelers Juggle Cash and Cards Abroad: Survey Insights

Updated Category News Views 60

Travel Spending: Balancing Convenience with Costs Navigating the financial landscape when you're a traveler abroad ain't always a walk in the park, folks. A fresh survey by Upgraded Points takes a gritty dive into how 1,500 globe-trotters juggle cash and cards while hopping across borders. The nitty-gritty? Messy exchange rates, sneaky fees, and the dreaded declined...

Continue Reading
Chip Earnings Fuel Market Gains Amid Volatility Dip

Updated Category News Views 23

Tech Earnings Drive Market Resilience Amid a climate of economic uncertainty, it's refreshing to see semiconductor and tech earnings offering a little backbone to the market. This week, the S&P 500 climbed 1.51%, while the Nasdaq Composite jumped 1.98% over three sessions. It's like watching Rocky get up off the mat—those indices pushing higher when it seemed like they...

Continue Reading

Top 5 Most Recently Viewed Articles

Fractyl Health and Bariendo Team Up for Innovative Obesity Care

Updated Category News Views 117

Fractyl Health and Bariendo Collaborate on Innovative Solutions Fractyl Health, Inc. (NASDAQ: GUTS), a company dedicated to pioneering new approaches to obesity treatment, has entered into an exciting partnership with Bariendo Inc., an all-in-one obesity care platform. This collaboration is a proactive step aimed at exploring the future of Fractyl’s investigational...

Continue Reading
Medpace's Challenges Emerge as Stock Downgraded by Baird

Updated Category News Views 378

Insights into Medpace's Recent Stock Downgrade Recently, Baird has reassessed its perspective on Medpace Holdings Inc. (NASDAQ: MEDP) by downgrading the stock rating from Outperform to Neutral. Alongside this change, they reduced the price target significantly from $413 to $349. This shift reflects the evolving challenges Medpace faces, despite their historical success in...

Continue Reading
Travere Therapeutics Reaches New Heights: Stock Performance Insights

Updated Category News Views 80

Travere Therapeutics Stock Performance Shines In a remarkable display of market confidence, Travere Therapeutics Inc. (TVTX) stock has reached a significant milestone by hitting a 52-week high of $18.63. This achievement reflects an impressive 171.22% increase in stock price over the past year, showcasing a period of substantial growth for the company. Investors have...

Continue Reading
Cizzle Brands Launches on Cboe Canada with Exciting Prospects

Updated Category News Views 89

Cizzle Brands Debuts on Cboe Canada Cboe Canada has recently welcomed Cizzle Brands Corporation as it makes its public markets debut, introducing an exciting chapter for the Canadian-based company specializing in sports nutrition. This debut under the trading symbol CZZL signifies a significant milestone as Cizzle seeks to expand its reach in the competitive market of...

Continue Reading
Concerns Raised About Waymo's Arrival in Atlanta Amid Safety Risks

Updated Category News Views 394

Concerns Over Self-Driving Cars in Atlanta As autonomous vehicles continue to grab headlines, Attorney Amy Witherite, a renowned traffic safety expert, has voiced significant concerns regarding their impending arrival in Atlanta. Recently, numerous incidents across various cities have illuminated the potential hazards associated with these self-driving cars. From...

Continue Reading